שילוב של פריזמה עם אבליפיי דחוף

שלום, אכן יש אינטראקציה בין שתי התרופות מבחינת ההשפעה על המטבוליזם של אבליפיי, מכיוון שפריזמה מעכבת מטבוליזם של אבליפיי. ולכן אין מניעה לשילוב אלא ניתן לשלב עם צורך בהפחתת מינון. מצרף רפרנס לרופא המטפל : Additional drug/group (CYP3A4 Inhibitors): Further aripiprazole dose reductions are recommended with concomitant use of a CYP3A4 inhibitor •Indication: Aripiprazole dose reduction is not recommended when used as adjunctive therapy for major depressive disorder. Risk Rating D: Consider therapy modification Summary CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole. Severity Moderate Reliability Rating Good Patient Management For aripiprazole formulations other than the extended-release injectable: decrease the aripiprazole dose to 50% of the usual dose when initiating concomitant therapy with a strong CYP2D6 inhibitor, and further to 25% of the usual dose in patients who are also receiving strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole). Dose reductions to 25% of the usual dose could also be considered when combining a strong CYP2D6 inhibitor with a less potent CYP3A4 inhibitor initially and then adjusted to achieve a favorable clinical response. For extended-release injectable aripiprazole: the following dose adjustments are recommended only when inhibitors are given for more than 14 days. In patients who would normally receive a 400 mg aripiprazole dose, reduce dose to 300 mg when given with a strong CYP2D6 inhibitor and further to 200 mg in patients who are also receiving strong CYP3A4 inhibitors; in patients who would normally receive a 300 mg dose, reduce dose to 200 mg when given with a strong CYP2D6 inhibitor and further to 160 mg in patients who are also receiving strong CYP3A4 inhibitors. Increase aripiprazole doses proportionately following discontinuation of treatment with CYP3A4 and/or CYP2D6 inhibitors. Aripiprazole dose adjustment is not recommended when used as adjunctive therapy in patients with major depressive disorder and receiving a CYP2D6 inhibitor. CYP2D6 Inhibitors (Strong) Interacting Members BuPROPion, Dacomitinib, FLUoxetine, PARoxetine*, QuiNIDine, Quinidine (Non-Therapeutic), Tipranavir מצרף את הרפרנס